Narsoplimab

Drug Overview

In the highly complex field of hematology, managing complications after a bone marrow or stem cell transplant is one of the most significant challenges for medical teams. Narsoplimab is a cutting-edge medication belonging to the MASP-2 Inhibitor drug class. It represents a specialized breakthrough for patients facing a rare but devastating condition known as Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (HSCT-TMA).

As a highly advanced BIOLOGIC and TARGETED THERAPY, narsoplimab is designed to stop the body’s immune system from accidentally attacking its own blood vessels following a transplant. By precisely blocking a specific enzyme in the blood, it helps prevent the formation of microscopic blood clots that can damage vital organs, particularly the kidneys and the brain.

• Generic Name: narsoplimab
• US Brand Names: Not yet assigned (previously known by the developmental code OMS721)
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: As of early 2026, narsoplimab has not received full FDA approval for HSCT-TMA. Following the 2021 Complete Response Letter (CRL), the drug remains in clinical trial phases and available only via Expanded Access/Compassionate Use, not as a standard-of-care FDA-approved indication.

What Is It and How Does It Work? (Mechanism of Action)

Narsoplimab is a fully human monoclonal antibody that acts as a TARGETED THERAPY for the lectin pathway of the complement system. Its molecular and hematological mechanism involves several key steps:

1. MASP-2 Inhibition: The drug specifically binds to and blocks MASP-2 (mannan-binding lectin-associated serine protease-2). MASP-2 is the “master switch” enzyme that triggers the lectin pathway.
2. Stopping the Chain Reaction: By shutting down MASP-2, narsoplimab prevents the immune system from creating a cascade of inflammatory proteins.
3. Endothelial Protection: Without the lectin pathway attacking the blood vessel walls, the inflammation in the tiny capillaries begins to subside.
4. Hemorrhage Risk Reduction and Clot Prevention: HSCT-TMA usually causes the blood to form tiny clots that “shred” red blood cells as they pass by. By stabilizing the blood vessel lining, narsoplimab stops this clotting process, preserving red blood cells and platelets and preventing organ-damaging micro-strokes.

FDA-Approved Clinical Indications

Primary Indication

The primary use for narsoplimab in hematology is the treatment of Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (HSCT-TMA). This condition occurs when the intense preparation for a transplant (chemotherapy or radiation) and the transplant itself cause widespread damage to the blood vessels. This leads to kidney failure, neurological issues, and a dangerous drop in blood counts. Narsoplimab is used specifically in high-risk patients to stop this vascular damage and improve survival rates.

Other Approved & Off-Label Uses

Research into MASP-2 inhibition is expanding rapidly. Other areas where narsoplimab is being utilized or studied include:

• IgA Nephropathy: A serious kidney disease where the lectin pathway causes inflammation in the kidney’s filtering units.
• Atypical Hemolytic Uremic Syndrome (aHUS): Another form of TMA driven by complement overactivity.
• Lupus Nephritis: Severe kidney inflammation caused by Systemic Lupus Erythematosus.
• COVID-19 Related Critical Care: Studied off-label for managing severe lung inflammation and vascular clotting in critically ill patients.

Dosage and Administration Protocols

Narsoplimab is administered as an intravenous infusion by a healthcare professional, usually in a hospital or specialized infusion center. Dosing is weight-based to ensure each patient receives the correct amount of this BIOLOGIC therapy.

Important Adjustments:

• Maximum Dose: The standard clinical dose is typically capped at 370 mg per infusion regardless of weight.
• Duration of Treatment: Therapy is usually continued for at least 4 to 8 weeks, depending on how quickly the patient’s blood markers (like LDH and platelet counts) normalize.
• Renal/Hepatic Insufficiency: As a monoclonal antibody, narsoplimab is not primarily cleared by the liver or kidneys in the traditional sense; therefore, dose adjustments for renal or hepatic impairment are generally not required, though close monitoring of the patient’s clinical status is mandatory.

Clinical Efficacy and Research Results

Current clinical study data (2020-2026) has shown that narsoplimab significantly improves outcomes for patients with high-risk HSCT-TMA, a population that previously had a mortality rate exceeding 80%.

In pivotal clinical trials, approximately 61% of patients treated with narsoplimab achieved a complete clinical response. This response is defined as the normalization of LDH levels (a marker of cell damage), stabilization of kidney function, and a significant increase in platelet and red blood cell counts without the need for frequent transfusions. Most importantly, research indicates that the 100-day survival rate for patients who respond to narsoplimab is significantly higher than for those receiving standard supportive care alone.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Safety Profile and Side Effects

Black Box Warning

There is currently no Black Box Warning for narsoplimab.

Common side effects (>10%)

• Nausea and vomiting
• Diarrhea
• Fatigue
• Fever (Pyrexia)
• Headache
• Small drops in blood pressure during infusion

Serious adverse events

• Severe Infections: Because narsoplimab blocks a part of the immune system, patients may be at a higher risk for serious bacterial or viral infections.
• Hypersensitivity: As with any BIOLOGIC, there is a risk of an allergic reaction (anaphylaxis) during the infusion.
• Infusion Reactions: Fever, chills, or rashes during the administration process.

Management Strategies

Patients should be pre-screened for any active infections before starting treatment. If an infusion reaction occurs, the nurse may slow the rate of the IV or provide medications like antihistamines or acetaminophen. If a serious infection develops during treatment, narsoplimab may be temporarily paused while the patient receives intensive antibiotic therapy.

Research Areas

Current research is exploring the role of MASP-2 inhibition in “long-haul” vascular complications. Active clinical trials are investigating whether narsoplimab can prevent chronic kidney disease in transplant survivors. Additionally, novel delivery systems, such as subcutaneous (under the skin) injections, are being researched to make the treatment more convenient for patients who have been discharged from the hospital. There is also significant interest in using MASP-2 inhibitors as a TARGETED THERAPY for other rare blood disorders involving the bone marrow and lymphatic system.

Patient Management and Practical Recommendations

Pre-treatment Tests

Before starting narsoplimab, doctors will perform several baseline diagnostics:

• CBC and Peripheral Smear: To check for “schistocytes” (fragmented red blood cells).
• LDH and Haptoglobin: To measure the severity of the blood cell destruction.
• Creatinine and Urinalysis: To assess baseline kidney function.
• Complement Levels: To evaluate the activity of the immune system.
• Infection Screen: Testing for baseline viral and bacterial status.

Precautions during treatment

• Transfusion Triggers: While on narsoplimab, doctors will carefully monitor when a patient needs a blood or platelet transfusion, aiming to see these needs decrease as the drug starts to work.
• Vigilance for Sepsis: Patients must be monitored closely for any signs of fever or sudden weakness, as their immune system is partially suppressed.
• Monitoring for Thromboembolism: Although the drug prevents micro-clots, the underlying TMA state still puts patients at risk for larger blood clots.

“Do’s and Don’ts” List

• DO report any fever, chills, or cough to your hematologist immediately.
• DO keep all scheduled twice-weekly infusion appointments; consistency is key to keeping the MASP-2 enzyme blocked.
• DO inform your medical team of all other medications you are taking, especially other immunosuppressants.
• DON’T stop treatment early without consulting your specialist, as the TMA symptoms may return aggressively.
• DON’T ignore signs of a “micro-stroke,” such as sudden confusion or changes in vision, even if they seem temporary.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment plan.